Kilgore Meredith L, Goldman Dana P
University of Alabama at Birmingham, School of Public Health, 1665 University Blvd. RPHB 330, Birmingham, AL 35294-0022, USA.
Contemp Clin Trials. 2008 Jan;29(1):1-8. doi: 10.1016/j.cct.2007.04.004. Epub 2007 May 6.
To estimate the effect of clinical trial participation on drug utilization, drug costs, and out-of-pocket expenditures for cancer patients.
The study used a national probability sample of patients participating in cancer clinical trials and a matched cohort of patients not enrolled in trials but receiving treatment for the same cancers from the same providers. Subjects were interviewed about prescription drug utilization and out-of-pocket drug expenditures. We estimated treatment costs based on a large pharmacy transaction database. Multivariate regression was used to estimate the effects of trial participation on drug costs and out-of-pocket expenditures.
Participants in clinical trials incurred higher prescription drug costs than non-participants: an average of $131 over a six-month period. However, there was no significant difference in out-of-pocket expenditures for the two groups.
Participation in clinical trials was associated with a modest increase in prescription drug utilization and costs, but these costs did not necessarily impose an economic burden on cancer trial participants.
评估参与临床试验对癌症患者药物使用、药物成本和自付费用的影响。
本研究采用了参与癌症临床试验患者的全国概率样本，以及未参加试验但接受来自相同医疗服务提供者的相同癌症治疗的匹配队列患者。就处方药使用情况和自付药物费用对受试者进行了访谈。我们基于一个大型药房交易数据库估算了治疗成本。采用多元回归分析来评估参与试验对药物成本和自付费用的影响。
临床试验参与者的处方药成本高于非参与者：在六个月期间平均高出131美元。然而，两组的自付费用没有显著差异。
参与临床试验与处方药使用和成本的适度增加相关，但这些成本不一定会给癌症试验参与者带来经济负担。
